FDA Approved: TURALIO — Supplemental Application (Daiichi Sankyo Inc.)

View source ↗

Summary

The FDA approved a supplemental application for TURALIO (pexidartinib hydrochloride) submitted by Daiichi Sankyo Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tenosynovial Giant Cell Tumor

Drugs mentioned

• TURALIO (pexidartinib)

Snippet

SUPPL AP for TURALIO (PEXIDARTINIB HYDROCHLORIDE)